Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Upstream Bio (UPB) from "hold" to "sell", joining other mixed analyst actions; despite this, the consensus across analysts remains a Moderate Buy with an average price target of $39.00.
• Shares plunged about 11.4% to open at $8.67 and are trading well below their 50-day ($15.93) and 200-day ($21.35) moving averages, with a market capitalization near $469 million.
• Upstream Bio reported a Q1 EPS of -$0.79, missing estimates, and shows negative profitability metrics (negative ROE and margins); analysts expect FY EPS of about -4.3.

Upstream Bio (NASDAQ:UPB - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

UPB has been the topic of a number of other research reports. Evercore cut Upstream Bio from an "outperform" rating to an "in-line" rating and set a $15.00 price objective for the company. in a report on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of Upstream Bio in a report on Wednesday, January 21st. Lifesci Capital initiated coverage on Upstream Bio in a research report on Tuesday, December 2nd. They issued an "outperform" rating and a $43.00 price target on the stock. Finally, Mizuho raised Upstream Bio to a "strong-buy" rating in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Upstream Bio presently has a consensus rating of "Moderate Buy" and an average price target of $39.00.

Upstream Bio Stock Down 11.4%

NASDAQ UPB opened at $8.67 on Friday. The firm has a 50-day moving average price of $15.93 and a two-hundred day moving average price of $21.35. Upstream Bio has a 12-month low of $5.14 and a 12-month high of $33.68. The company has a market capitalization of $468.53 million, a P/E ratio of -3.25 and a beta of 2.96.

Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its earnings results on Thursday, March 26th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.06). Upstream Bio had a negative return on equity of 34.90% and a negative net margin of 5,026.03%.The business had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.52 million. Equities analysts expect that Upstream Bio will post -4.3 EPS for the current year.

Hedge Funds Weigh In On Upstream Bio

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in shares of Upstream Bio during the 4th quarter worth $29,000. Torren Management LLC acquired a new position in Upstream Bio during the fourth quarter worth about $30,000. Empowered Funds LLC acquired a new position in Upstream Bio during the fourth quarter worth about $45,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Upstream Bio in the fourth quarter worth about $71,000. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Upstream Bio by 1,963.9% in the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company's stock worth $57,000 after acquiring an additional 2,887 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio's approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company's research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.